How to Get a Wegovy Prescription: Eligibility, Cost, and Options

A Wegovy (semaglutide) prescription requires a licensed clinician’s evaluation. Most adults meet FDA-label BMI criteria at 30 or higher, or 27+ with a weight-related condition like high blood pressure, high cholesterol, sleep apnea, or type 2 diabetes. The FDA-approved Wegovy product is a weekly injection; oral semaglutide with SNAC has been studied and described by Novo Nordisk, but patients should verify current FDA labeling with a clinician [1,2].

Quick facts about getting a Wegovy prescription

Wegovy prescriptions require a clinician visit, either online or in person, and the core FDA-label adult BMI thresholds are 30+ or 27+ with a weight-related condition [1]. The key question is whether the expected benefit is likely to outweigh the risks for your medical situation, including BMI, weight-related conditions, current medicines, side effects, and contraindications [1].

• Wegovy is a brand-name semaglutide injection made by Novo Nordisk and belongs to the GLP-1 receptor agonist drug class [1].
• Ozempic is also semaglutide, but it is FDA-approved for type 2 diabetes and cardiovascular risk reduction in certain adults with type 2 diabetes, not for chronic weight management [3].
• Zepbound is tirzepatide, a different injectable medication that activates GIP and GLP-1 receptors and is FDA-approved for chronic weight management in eligible adults; it has its own warnings and contraindications [4].
• Insurance plans may require prior authorization before covering Wegovy, even when a patient meets FDA-label criteria.
• Compounded semaglutide via a state-licensed 503A pharmacy is not FDA-approved and should be discussed separately from brand Wegovy [9].

What is Wegovy and who is it for?

Wegovy is semaglutide, a GLP-1 receptor agonist, meaning it acts on glucagon-like peptide-1 receptors involved in appetite, stomach emptying, and blood sugar regulation [1]. It is FDA-approved for specific groups, including adults meeting BMI criteria and adolescents age 12 and older with obesity, but safety risks and contraindications must be reviewed before prescribing [1].

Semaglutide, the active ingredient

Semaglutide is the active ingredient in Wegovy and Ozempic, but the products have different FDA-approved indications and dosing labels [1,3]. In the STEP 1 trial, adults without diabetes who received semaglutide 2.4 mg once weekly plus lifestyle intervention had greater average weight loss than those receiving placebo; nausea, diarrhea, vomiting, and constipation were more common with semaglutide, and individual results vary [5].

FDA-approved uses: weight management, cardiovascular risk reduction, and MASH

Wegovy is FDA-approved to reduce excess body weight and maintain weight reduction long term in eligible adults and adolescents age 12 and older with obesity [1]. It is also FDA-approved to reduce the risk of major adverse cardiovascular events, or MACE, in adults with established cardiovascular disease and either obesity or overweight; in the SELECT trial, participants received semaglutide 2.4 mg once weekly, and MACE risk was lower than with placebo, while gastrointestinal side effects led to more discontinuations in the semaglutide group [6].

Wegovy is also FDA-approved for adults with metabolic dysfunction-associated steatohepatitis, or MASH, with moderate to advanced liver fibrosis, when used with a reduced-calorie diet and increased physical activity [1]. In a phase 2 trial of semaglutide in nonalcoholic steatohepatitis, NASH resolution was more common with semaglutide than placebo, while gastrointestinal adverse events were also more common; individual results vary [7].

Who qualifies for a Wegovy prescription?

Wegovy BMI requirements are based on FDA-label criteria and clinician judgment. Adults may meet criteria at BMI 30 or higher, or BMI 27 or higher with at least one weight-related condition, but contraindications, side effects, pregnancy status, and medication interactions must be reviewed before prescribing [1].

BMI thresholds: 30+, or 27+ with a comorbidity

For adults, the Wegovy label includes people with obesity, defined as BMI 30 kg/m² or higher, or overweight, defined as BMI 27 kg/m² or higher, with at least one weight-related condition such as hypertension, dyslipidemia, or type 2 diabetes [1]. A clinician may also review sleep apnea, cardiovascular disease, liver disease, kidney function, eating disorder history, and medication interactions before deciding whether Wegovy is appropriate.

Adolescents 12 and up

Wegovy is FDA-approved for chronic weight management in adolescents age 12 and older with obesity, based on age- and sex-specific BMI criteria [1]. In the STEP TEENS trial, participants received once-weekly semaglutide 2.4 mg plus lifestyle intervention, and BMI decreased more than with placebo; gastrointestinal adverse events and gallbladder-related events occurred more often with semaglutide, and individual results vary [8].

Who cannot take Wegovy

Wegovy is contraindicated in people with a personal or family history of medullary thyroid carcinoma, or MTC, and in people with Multiple Endocrine Neoplasia syndrome type 2, or MEN 2 [1]. It should also be stopped when pregnancy is recognized, and people planning pregnancy should discuss timing with a clinician because weight loss medications are not recommended during pregnancy [1].

A clinician will also screen for pancreatitis history, gallbladder disease, kidney problems, diabetic retinopathy in people with type 2 diabetes, mental health concerns, and medicines that may raise low-blood-sugar risk [1]. Common side effects include nausea, vomiting, diarrhea, constipation, abdominal pain, headache, fatigue, dizziness, and reflux [1].

Is it hard to get approved for Wegovy?

Getting approved for Wegovy can mean two different things: clinical approval by a prescriber and payment approval by insurance. A patient may meet FDA-label criteria, including BMI 30+ or 27+ with a qualifying condition, but an insurer may still deny coverage or ask for more paperwork.

Clinical eligibility vs. insurance approval

Clinical eligibility is the medical decision: your clinician checks whether Wegovy is appropriate based on BMI, conditions, contraindications, medications, side effects, and risks [1]. Insurance approval is the payer decision: your plan decides whether Wegovy is covered under your pharmacy benefit and whether your documentation meets its rules.

Prior authorization and step therapy

Prior authorization means your prescriber must send information to the insurer before the plan decides whether it will pay. Some plans may ask for BMI documentation, diagnosis codes, prior lifestyle attempts, chart notes, or proof that other options were tried first, a process often called step therapy.

How do I get a Wegovy prescription? Step by step

To get a Wegovy prescription, you need a medical evaluation and a prescription from a licensed clinician. The visit can happen through primary care, an obesity medicine clinician, an endocrinology clinic, or telehealth, and the clinician must review FDA-label safety issues before any weekly injection is prescribed [1].

1. 1Choose a care path: in-person primary care, obesity medicine, endocrinology, or telehealth.
2. 2Share your height, weight, BMI, weight history, medical conditions, medications, allergies, pregnancy plans, and family history of MTC or MEN 2.
3. 3The clinician reviews risks, benefits, contraindications, side effects, and alternatives such as tirzepatide, lifestyle care, or non-GLP-1 medicines [1,4].
4. 4If Wegovy is appropriate, the clinician may send a prescription to a pharmacy and help with prior authorization if your plan requires it.
5. 5You schedule follow-up to review side effects, response, labs when needed, and whether the treatment plan should continue.

In-person primary care or obesity medicine visit

An in-person clinician can measure weight, blood pressure, waist size, and related health markers. This can be useful if you have complex medical history, active symptoms, advanced kidney disease, pregnancy concerns, eating disorder history, or multiple medications that need careful review [1].

Telehealth evaluation

Telehealth can be a practical way to be evaluated for Wegovy when a clinician can safely review your history and follow state prescribing rules. Chia is one licensed telehealth option that offers clinician-reviewed evaluations for brand Wegovy when appropriate and compounded semaglutide through 503A pharmacy partners when that separate, non-FDA-approved option is clinically suitable.

What labs and history a clinician reviews

Labs are not identical for every patient, but clinicians often review A1C or glucose, kidney function, liver enzymes, lipids, pregnancy status when relevant, and prior records. The Wegovy label warns about pancreatitis, gallbladder disease, acute kidney injury, hypoglycemia risk with insulin or insulin secretagogues, heart rate increase, and suicidal behavior monitoring [1].

Wegovy pill vs. Wegovy injection: which will I be prescribed?

Wegovy injection is the established weekly semaglutide formulation in the FDA label, while the “Wegovy pill” usually refers to oral semaglutide formulated with SNAC, an absorption enhancer, that has been studied and described by Novo Nordisk [1,2]. Which form is appropriate depends on current FDA labeling, availability, safety review, coverage, adherence, side effects, and clinician judgment; the FDA-approved injectable label includes a once-weekly schedule [1].

How much does Wegovy cost per month?

Wegovy cost per month depends on insurance, pharmacy, savings offers, dose form, and whether you use brand medication or a compounded option. The list price is not always what a patient pays, so the most useful monthly estimate comes from your insurance plan and pharmacy [10].

Cash price

Novo Nordisk’s patient support and pharmacy resources provide current pricing and savings information for Wegovy, but pharmacy cash prices can vary by location and benefit status [10]. If you are paying cash, ask the pharmacy for the exact out-of-pocket price before pickup.

Novo Nordisk savings offers

NovoCare lists manufacturer savings and support options for eligible patients, and the terms can change over time [10]. Manufacturer offers may not apply to all insurance types, and government insurance programs often have different rules.

Medicare and commercial insurance

Commercial plans vary widely in obesity medication coverage. Medicare coverage may depend on the FDA-approved use and plan rules, including cardiovascular risk reduction criteria for some patients, so the plan’s formulary and prior authorization policy matter [1].

Compounded semaglutide as a lower-cost alternative

Compounded semaglutide may cost less than brand Wegovy in some settings, but it is not FDA-approved, is not therapeutically equivalent to brand Wegovy, and should only be used when prescribed for an individual patient and prepared by an appropriately licensed pharmacy [9]. FDA notes that compounded drugs are not reviewed for safety, effectiveness, or quality before they are marketed, so patients should ask about the pharmacy, ingredient source, sterility practices, adverse-event reporting, side effects, and contraindications [9].

How to get Wegovy through Chia

A telehealth evaluation can review eligibility in one care pathway, but it is still a real medical visit. Through Chia, a licensed clinician reviews your health history, current medications, BMI, contraindications, side effects, and treatment goals, then decides whether brand Wegovy, compounded semaglutide through a 503A pharmacy, tirzepatide, or another plan is appropriate; compounded semaglutide remains a separate, non-FDA-approved option [1,4,9].

Clinician-reviewed telehealth evaluation

A telehealth clinician may ask for your height, weight, blood pressure history, diagnoses, medication list, prior labs, pregnancy status, and family history of MTC or MEN 2. This helps screen for risks listed in the Wegovy prescribing information, including thyroid C-cell tumor warning, pancreatitis, gallbladder disease, kidney injury, hypoglycemia risk with certain diabetes medicines, and suicidal behavior monitoring [1].

Brand Wegovy vs. compounded semaglutide via a 503A pharmacy

Brand Wegovy is FDA-approved and has a specific prescribing label [1]. Compounded semaglutide is a separate, non-FDA-approved option prepared for an individual patient by a licensed compounding pharmacy when a clinician determines it is appropriate; FDA does not review compounded drugs for safety, effectiveness, or quality before dispensing [9].

What should you expect after your first Wegovy prescription?

After a first Wegovy prescription, the next steps are pharmacy fulfillment, insurance paperwork if needed, side-effect monitoring, and follow-up. The early weeks are usually focused on tolerability and safety rather than rushing dose changes; the FDA-approved label describes dose steps at 4-week intervals [1].

Dose escalation schedule

The FDA-approved Wegovy injection label starts semaglutide at 0.25 mg once weekly for weeks 1 through 4, then increases in steps at 4-week intervals toward maintenance doses listed in the prescribing information [1]. This is label information, not personal dosing advice; your clinician decides whether to start, pause, continue, or stop based on your response, side effects, and safety factors.

Wegovy HD 7.2 mg has been discussed as a higher-dose semaglutide program by Novo Nordisk, but any higher-dose product or dose form should be checked against the current FDA label before use [1,2]. A non-labeled dose or product should not be used unless a licensed clinician confirms it is appropriate and legally available.

Managing common side effects

The most common Wegovy side effects in the label include nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, bloating, belching, low blood sugar in some patients with type 2 diabetes, gas, gastroenteritis, and reflux [1]. Severe or persistent abdominal pain, signs of dehydration, allergic symptoms, gallbladder symptoms, mood changes, or pregnancy should prompt medical contact right away [1].

Follow-up visits

Follow-up helps your clinician check side effects, weight trend, blood pressure, glucose markers when relevant, medication interactions, and whether the benefit still outweighs risk [1]. If Wegovy is not tolerated, alternatives may include changing the treatment plan, considering another FDA-approved medication such as tirzepatide when appropriate, or focusing on non-medication care [4].

Frequently asked questions

Keep reading

GLP-1 Weight Loss

How to Get a GLP-1 Prescription Online: Options, Costs, and Eligibility

GLP-1 Weight Loss

How to Get a GLP-1 Prescription Online: What to Expect, Who Qualifies, and What It Costs

GLP-1 Medications

Online Pharmacy for Ozempic: How to Get a Prescription and Delivery Safely